World Parkinson’s day 2022
In time for World Parkinson’s day 2022, we present our first data utilizing a newly created C. elegans model to help prioritise a subset of PD GWAS genes worthy of further functional investigation.
This is the first systematic large-scale screening of ~100 risk genes for PD identified in recent years.
We generated a new C. elegans PD model that exhibits a readout for developed alpha-Synuclein inclusions in dopaminergic neurons, and follows their degeneration during aging. We then used these animals for functional screen of evolutionarily conserved risk genes for PD identified from the most recent GWAS data.
We performed a reverse genetic screen of ~100 Parkinson's disease (PD) risk genes that revealed new modulators of alpha-Synuclein neurotoxicity, a pathological hallmark of PD in humans.
Genome wide association studies over the years have revealed tens of risk signals linked to the idiopathic PD cases, however large majority of the genes located around these signals have not yet been functionally validated.
We recently published a study and we found 28 novel modulators of alpha-Synuclein-induced neuronal pathogenesis in this model, which should be further investigated functionally as potential new therapeutic targets for synucleinopathies, aging-related neurodegenerative diseases that include Parkinson’s disease.
Preprint summary is available in the Frontiers journal at this link: https://www.frontiersin.org/articles/10.3389/fnagi.2022.806000/abstract
- Validating the role of these genes in vertebrate animal model systems and human cell models for PD.
- Deep investigation of the mechanisms modulating neuronal pathogenesis in C. elegans models.
In the image you can see the microscopic nematode C. elegans with visualized dopaminergic neurons undergoing neurodegeneration. This new animal model help us to investigate the pathogenetic role of risk genes for Parkinson's disease, and other neurodegenerative diseases associated with aging at the level of the whole living organism.
The project was funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 844497, and by the Department of Educational Assistance, University and Research of the Autonomous Province of Bolzano, Italy.
Other News & Events
19 May 2022
New Job Position
We are looking for a Researcher or technician with experience in analytical chemistry for generation of a large-scale targeted metabolomics data set.
21 March 2022
Epigenetic reprogramming of cancer cells by a small chemical compound
An international team of scientists, recently published a study demonstrating the beneficial effects of a particular group of chemical compounds on the epigenetic landscape in a specific and ...
28 February 2022
Two new positions opened
Job positions opened at our Institute: Biomedical laboratory technician & Technician in IT Engineering/Development/System administration.
03 February 2022
New job position
Our Institute is looking for a Senior Researcher focusing on Ethical-legal aspects of Biomedical Research. Deadline:15 March 2022
23 December 2021
Job opportunities at the Institute for Biomedicine
Are you looking for a new job challenge? We are hiring.
02 December 2021
Lo studio CHRIS riprende il follow-up dei 13 mila partecipanti
Dopo la sospensione imposta dalla pandemia, il centro CHRIS dell’Ospedale di Silandro torna a popolarsi. Per gli oltre 13 mila abitanti della Val Venosta entrati a far parte dello studio tra il 2011 e ...
14 October 2021
EPIC at the NOI project fair
The yearly EFRE project fair on October 22nd is the perfect opportunity to meet us, we are presenting EPIC at booth 13.
13 October 2021
CHRIS COVID-19 study protocol available to the scientific community
Available in Open Access, it represents a resource for researchers who want to replicate similar studies.